ties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
firstname.lastname@example.org Champions Oncology, Inc.
(Dollars in thousands except per share amounts)Reconciliation of GAAP to Non-GAAP Net LossThree Months Ended October 31,Six Months Ended October 31,2012201120122011Net loss – GAAP
1,868 Stock-based compensationNet loss - non-GAAP
($2,519) Reconciliation of GAAP to Non-GAAP Earnings Per Share (EPS)Three Months Ended October 31,Six Months Ended October 31,2012201120122011EPS – GAAP
0.04Effect of stock-based compensation on EPSEPS - non-GAAP
($0.05) Condensed Consolidated Statements of Operations (Unaudited)Three MonthsEnded October 31,Six MonthsEnded October 31,2012201120122011POS operating revenue
$1,188TOS operating revenue
2,184 Total operating revenue$1,458$1,741$3,564$3,372Cost of POS
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
|SOURCE Champions Oncology, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities2
. Champions Oncology Reports Financial Results for the Year Ended April 30, 20123
. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium4
. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response5
. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer6
. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology7
. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal8
. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA9
. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress10
. International Oncology Innovators Meeting in Hamburg11
. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs